Fresh analysis reveals that people who discontinue blockbuster slimming jabs like Mounjaro or Wegovy tend to recover reduced body mass much more quickly than those who end conventional diet and exercise programs.
Findings released in a major health publication demonstrates that while overweight individuals can lose a large proportion of their total mass while on the medication, the mass comes back at an average rate of 0.8 kg per month after stopping.
"People buying these drugs should be informed of the risk of rapid weight regain when the treatment is stopped," warns expert Dr. Susan Jebb.
That rate of recovery suggests a return to starting mass in about a year and a half.
Comparing Treatments
The study, which reviewed dozens of trials involving over 9,000 of participants, compared the outcomes of the injectable medications with older methods.
Researchers point out that people who lose weight through dieting typically see a slower weight regain—perhaps 100 grams monthly—after stopping.
Understanding the Quick Rebound
Doctors suggest the mechanism of the injections accounts for the accelerated regain.
The injections imitate a body's own chemical called GLP-1, which helps regulate hunger.
"Sustained high doses of GLP-1 concentrations far above than the body's typical production may cause the system to generate a reduced amount of its endogenous GLP-1, and could lessen responsiveness to its actions," said Dr. Adam Collins, a nutrition specialist.
"Discontinuation of this medication means hunger is unsuppressed, making binge eating much more probable."
A Lifelong Condition?
Medical guidelines advise the injections for individuals with weight-linked medical conditions, alongside prescribed lifestyle changes.
Many experts contend that, due to the significant potential of weight regain, the treatment is often long-term.
This perspective is reinforced by pharmaceutical companies, who say that the results "emphasize the chronic nature of obesity," comparing it to managing diseases like high blood pressure.
User Accounts
Users who have stopped the medication explain a powerful return of appetite.
"I experienced a switch flipping and I was suddenly extremely hungry," described one woman.
This challenge is compounded if patients have not established sustainable lifestyle or habit modifications during treatment.
Widespread Use
Figures suggest that a significant number of adults in the UK have tried weight-loss jabs in the past year, with interest being substantial.
- Adoption is higher among females compared to men.
- The middle-aged age group shows the greatest usage rates.
- Many obtain the medications through private healthcare rather than public health services.
In conclusion, clinicians caution that while GLP-1 drugs are effective tools for weight loss, they are not a magic fix and maintained weight loss hinges on ongoing lifestyle support.
